CCM
RCKT icon

Copernicus Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Copernicus Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-8,000
Closed -$355K – 15
2021
Q1 		$355K Hold
8,000
– – 5.74% 7
2020
Q4 		$439K Buy
+8,000
New +$292K 6.84% 5

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Copernicus Capital Management's RCKT Position: Q2 2021 in Review

Copernicus Capital Management sold out of Rocket Pharmaceuticals (RCKT) in Q2 2021, closing a stake of 8,000 shares — an estimated $355K sold.

Copernicus Capital Management first reported a position in RCKT in Q4 2020 and held it in 2 quarters. The position peaked at $439K in Q4 2020. 150 funds tracked by Wall St. Rank hold RCKT as of Q2 2021.

  • Copernicus Capital Management reported no remaining Rocket Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Copernicus Capital Management sold 8,000 Rocket Pharmaceuticals shares in Q2 2021, an estimated $355K.
  • Copernicus Capital Management first reported a position in Rocket Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Copernicus Capital Management's Rocket Pharmaceuticals position peaked at $439K in Q4 2020.
  • 150 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2021.

Based on Copernicus Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.